Search results
Feb 17, 2022 · On an adjusted basis, 2021 net income attributable to Baxter totaled $1.8 billion, or $3.61 per diluted share, an increase of 17% compared to the prior-year period. Adjusted results for full-year 2021 include a contribution to earnings of $0.08 per diluted share from Hillrom.
- Baxter Reports Fourth-Quarter and Full-Year 2022 Results
The accompanying schedules include additional details on...
- Baxter Reports Fourth-Quarter and Full-Year 2022 Results
Feb 9, 2023 · The accompanying schedules include additional details on sales performance by product categories and segments. For full-year 2022, net income (loss) attributable to Baxter totaled ($2.4 billion), or ($4.83) per diluted share on a U.S. GAAP basis.
Apr 28, 2022 · For full-year 2022: Baxter now expects U.S. GAAP earnings of $2.35 to $2.43 per diluted share and adjusted earnings, before special items, of $4.12 to $4.20 per diluted share. The company expects sales growth of 23% to 24% on a reported basis, 25% to 26% on a constant currency basis and approximately 3% on an operational basis.
Feb 17, 2022 · Fourth quarter adjusted earnings per share were $1.04, up 30% year-over-year. Hillrom contributed $212 million in sales and $0.08 of adjusted earnings per share in the quarter. For full year...
2022 Financial Outlook For full-year 2022: Baxter now expects U.S. GAAP earnings of $2.35 to $2.43 per diluted share and adjusted earnings, before special items, of $4.12 to $4.20 per diluted share. The company expects sales growth of 23% to 24% on a reported basis, 25% to 26% on a constant
Feb 21, 2024 · Baxter is an established market leader in big pharma and medical supplies, with expected EPS growth and declining debt. Learn why BAX stock is a Buy.
People also ask
What will Baxter's earnings look like in 2022?
What does Baxter expect in 2022?
What is Baxter's fourth-quarter 2021 earnings outlook?
How did Baxter perform in 2021?
What is Baxter's financial outlook for 2022?
What was Baxter's net income in the fourth quarter?
Baxter net income for the twelve months ending June 30, 2024 was $2.476B, a 186.79% decline year-over-year. Baxter annual net income for 2023 was $2.656B, a 209.17% decline from 2022. Baxter annual net income for 2022 was $-2.433B, a 289.49% decline from 2021.